Divalent Chalcogen Or Acyclic Nitrogen Double Bonded Directly At Both 2- And 4- Positions, Or Tautomeric Equivalent (e.g., Hydantoin, Etc.) Patents (Class 514/389)
-
Patent number: 7960560Abstract: The invention relates to A 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivative having the general Formula I wherein R1 is H, (C1-6)alkyl (optionally substituted with oxo, OR4, COOR5, halogen or CN), (C2-6)alkenyl, (C2-6)alkynyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl; R2 and R2? are independently H or (C1-3)alkyl; or R2 and R2? form together with the carbon atom to which they are bound a (C3-5)cycloalkyl group; R3 represents H or 1 to 4 F substituents; Y represents or NR8R9; X represents CHR6, CF2, O, S, SO or SO2; R4 and R5 are (C1-6)alkyl; R6 is H, OR7 or CN; R7 is (C1-3)alkyl; R8 is (C5-7)cycloalkyl comprising a heteroatom selected from O, S, SO and SO2; R9 is H or (C1-4)alkyl; o and m represent the ortho or meta position of the substituent Y—CH2; or a pharmaceutically acceptable salt thereof; as well as to the use of said 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivatives in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, canceType: GrantFiled: December 1, 2009Date of Patent: June 14, 2011Assignee: N.V. OrganonInventors: Marcelis van der Stelt, Joseph Maria Gerardus Barbara Cals
-
Publication number: 20110136882Abstract: Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise I) contacting exterior surfaces of the live animal at least once with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one N,N?-bromochloro-5,5-dialkylhydantoin, such contacting occurring at least once when the animal is en route to being slaughtered but before it is killed by exsanguination; or II) contacting the carcass of the animal, after exsanguination, with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one N,N?-bromochloro-5,5-dialkylhydantoin or III) contacting at least one raw meat product and/or at least one processed meat product derived from the carcass. The contacting can be done one or more times in each of I), II), and III). Considerable advantages, which are described, are realized when using such methods.Type: ApplicationFiled: February 3, 2011Publication date: June 9, 2011Applicant: ALBEMARLE CORPORATIONInventors: James L. McNaughton, Eric W. Liimatta
-
Patent number: 7951822Abstract: The object is to provide a novel LXR? agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: March 30, 2009Date of Patent: May 31, 2011Assignee: Kowa Company, Ltd.Inventors: Ayumu Okuda, Takayuki Matsuda, Toru Miura, Koichi Yamazaki, Yuki Yamaguchi, Minoru Koura, Sayaka Kurobuchi, Yuichiro Watanabe, Kimiyuki Shibuya
-
Patent number: 7943389Abstract: Methods for determining chlorine demand in water are provided. One method comprises (a) providing a test water sample containing at least one contaminant and a source of chlorine and a source of bromide; (b) heating the test water sample for a suitable time and temperature sufficient to substantially oxidize the at least one contaminant in the test water sample; and (c) determining the content of residual chlorine present in the test water sample.Type: GrantFiled: August 30, 2006Date of Patent: May 17, 2011Assignee: Chemtura CorporationInventor: Karen Rigsby
-
Patent number: 7923036Abstract: Compositions comprising a mixture of (a) a major amount of solid halogen-containing sanitizer material and (b) a minor amount of calcium oxide modified particulate boric acid, the amount of calcium oxide modified particulate boric acid being sufficient to enable the composition to be classified as a class 1 or class 2 NFPA oxidizer are described. Also described is particulate boric acid at least a portion of the particles thereof having on their surface at least a partial coating of calcium oxide, and a method for preparing such coated particulate boric acid.Type: GrantFiled: September 30, 2008Date of Patent: April 12, 2011Assignee: PPG Industries Ohio, Inc.Inventor: Stanley R. Pickens
-
Patent number: 7919509Abstract: To provide a novel LXR? agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: February 27, 2009Date of Patent: April 5, 2011Assignee: Kowa Company, Ltd.Inventors: Ayumu Okuda, Takayuki Matsuda, Toru Miura, Hidefumi Ozawa, Ayako Tosaka, Koichi Yamazaki, Yuki Yamaguchi, Sayaka Kurobuchi, Yuichiro Watanabe, Kimiyuki Shibuya
-
Patent number: 7910615Abstract: A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.Type: GrantFiled: January 28, 2005Date of Patent: March 22, 2011Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
-
Publication number: 20110053918Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.Type: ApplicationFiled: June 27, 2008Publication date: March 3, 2011Inventors: Zhaoning Zhu, William J. Greenlee, Robert D. Mazzola, JR., Jun Qin, Xianhai Huang, Anandan Palani
-
Publication number: 20110021587Abstract: Methods are provided for reducing or eliminating bacteria such as Salmonella in eggs for human consumption through the use of at least one N,N-dihalo-5,5-dialkylhydantoin in which each of the alkyl groups independently comprises from 1 to about 6 carbon atoms.Type: ApplicationFiled: March 25, 2009Publication date: January 27, 2011Applicant: Albemarle CorporationInventors: George W. Cook, JR., Christopher J. Nalepa, Joe D. Sauer
-
Patent number: 7868181Abstract: The present invention relates to new compounds of formula I, where R1 and R2 are independently halo or C1-3haloalkyl, X is ethenyl or ethynyl, or a salt thereof.Type: GrantFiled: November 20, 2008Date of Patent: January 11, 2011Assignee: AstraZeneca ABInventors: Carmen Leung, Miroslaw Tomaszewski, Simon Woo
-
Publication number: 20100305177Abstract: A prophylactic or therapeutic agent for diabeticmaculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2?,5?-dioxospiro chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.Type: ApplicationFiled: July 23, 2010Publication date: December 2, 2010Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Noriaki KATO, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
-
Publication number: 20100298381Abstract: In its many embodiments, the present invention provides a novel class of 5-membered, nitrogen-containing heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.Type: ApplicationFiled: September 25, 2008Publication date: November 25, 2010Inventors: Zhaoning Zhu, William J. Greenlee, John P. Caldwell, Robert D. Mazzola, JR., Brian McKittrick, Chad E. Bennett, Duane A. Burnett
-
Publication number: 20100273849Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.Type: ApplicationFiled: January 26, 2010Publication date: October 28, 2010Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
-
Publication number: 20100273848Abstract: Compounds, compositions and methods for the treatment of cancer are disclosed herein. Embodiments of the present invention include compounds having the formula: (I), wherein R1 is selected from hydrogen or substituted or unsubstituted (C1-C6) alkyl or (C3-C6) cycloalkyl, R2 and R3 are independently selected from hydrogen, substituted or unsubstituted (C1-C6) alkyl, (C4-C6) cycloalkyl, or taken together with the N atom to which they are attached form a 3-6 membered heterocycloalkyl, and n is 1-5. Embodiments of the present invention also include pharmaceutical compositions comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof, and methods of treating cancer via the administration of such compounds to patients in need of such treatment.Type: ApplicationFiled: March 14, 2008Publication date: October 28, 2010Applicant: THE ARIZONA BD OR REG ON BEHALF OF THE UNIV OF AZInventors: Ross O. Meyers, Robert T. Dorr
-
Publication number: 20100267791Abstract: According to the invention, a method for the prevention of microbial growth in process waters is provided, wherein first a peracid compound, and thereafter a halogenated dialkyl hydantoin are dosed into said process water. Further, according to the invention, a combination for the prevention of microbial growth is provided, said combination comprising compounds to be dosed separately, said compounds being a peracid compound to be dosed first, and a halogenated dialkyl hydantoin to be dosed after the peracid compound, the weight ratio of the peracid compound to the halogenated dialkyl hydantoin being at least 2:1, wherein the amount of the peracid compound is calculated as active agent, while the amount of halogenated dialkyl hydantoin is calculated as active chlorine.Type: ApplicationFiled: November 7, 2007Publication date: October 21, 2010Inventors: Marko Kolari, Antti Heinänen
-
Publication number: 20100256209Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: ApplicationFiled: October 15, 2009Publication date: October 7, 2010Inventor: Jean-Louis Henri Dasseux
-
Publication number: 20100247583Abstract: Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.Type: ApplicationFiled: March 5, 2010Publication date: September 30, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Thibaud PORTAL, Laurence DUMAIS, Jérôme AUBERT, Laurent LAMY
-
Patent number: 7803826Abstract: The present invention provides a compound represented by formula (I): wherein n is an integer selected from 1 to 20, Q is A is cyano or the like; B is hydrogen, halogen, or the like; X1 and X2 are each independently selected from O and S; E is a C1-4 alkyl group; and R1, R2, R3 and R4 are each independently selected from a hydrogen atom and a C1-C6 alkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.Type: GrantFiled: August 3, 2005Date of Patent: September 28, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kazutaka Tachibana, Haruhiko Sato, Masateru Ohta, Mitsuaki Nakamura, Takuya Shiraishi, Ikuhiro Imaoka, Hitoshi Yoshino, Masahiro Nagamuta, Hiromitsu Kawata
-
Publication number: 20100233166Abstract: Compounds, compositions and methods for the treatment of malignancy are disclosed.Type: ApplicationFiled: April 13, 2010Publication date: September 16, 2010Inventors: George C. Prendergast, Alexander J. Muller, James B. Duhadaway, William Malachowski
-
Publication number: 20100216856Abstract: The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.Type: ApplicationFiled: January 30, 2008Publication date: August 26, 2010Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Sookja Kim Chung, Stephen Chung, Chihiro Hibi
-
Publication number: 20100216855Abstract: Imidazolone derivatives, as medicaments, of formula wherein: R1?H, C1 to C5 alkyl, aryl or a 5- or 6-membered heterocyclic group; Ar1=optionally substituted aryl or an aromatic heterocycle; R?R2—S—, R3—HN—, R4COHN or Ar2, with R2=a C1-C5 alkyl, vinyl or vinyl(C1-C5)alkyl, nitrile or nitrile(C1-C5)alkyl, aryl or benzyl radical, which are optionally substituted; R3=the meanings given above and H; Ar2=substituted or unsubstituted aryl.Type: ApplicationFiled: August 1, 2008Publication date: August 26, 2010Inventors: Francois Carreaux, Jean-Pierre Bazureau, Steven Renault, Laurent Meijer, Olivier Lozach
-
Publication number: 20100210698Abstract: A pesticidal composition comprising [2,5-dioxo-3-(2-propynyl)-1-imidazolidinyl]methyl 3-(2-methyl-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate as active ingredients, and a pests-controlling method characterized by applying an effective amount of said pesticidal composition to the pests or a locus where the pests inhabit, have an excellent controlling effect on the pests.Type: ApplicationFiled: September 3, 2008Publication date: August 19, 2010Inventor: Yoshito Tanaka
-
Patent number: 7772403Abstract: A novel process for the preparation of hydantoin sulfonyl chlorides of general formula (I) wherein R and n are as specified in the description, and certain novel intermediates thereto, are disclosed.Type: GrantFiled: March 15, 2007Date of Patent: August 10, 2010Assignee: AstraZeneca ABInventors: Philip Cornwall, Daniel Horner
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Patent number: 7759366Abstract: This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R?, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.Type: GrantFiled: February 5, 2009Date of Patent: July 20, 2010Assignee: Sanofi-AventisInventors: Gerhard Jaehne, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Irvin Winkler
-
Patent number: 7758890Abstract: Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field.Type: GrantFiled: March 1, 2004Date of Patent: July 20, 2010Assignee: Lyotropic Therapeutics, Inc.Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
-
Patent number: 7745637Abstract: Novel PDF inhibitors and novel methods for their use are provided.Type: GrantFiled: February 16, 2007Date of Patent: June 29, 2010Assignee: GlaxoSmithKline LLCInventors: Kelly M. Aubart, Ajita Bhat, Sigfried B. Christensen, IV, Jack D. Leber, Xiangmin Liao
-
Publication number: 20100160400Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.Type: ApplicationFiled: March 4, 2010Publication date: June 24, 2010Applicant: LYOTROPIC THERAPEUTICS, INC.Inventors: David Anderson, Benjamin G. Cameransi, JR., Vincent M. Conklin
-
Patent number: 7741354Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, wherein: R1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R2 represents alkyl, which may optionally be substituted by one or more groups selected from amino, halogen, hydroxyl, -alkoxy, -thioalkyl, —C(O)O-alkyl and —C(O)OH; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, haloalkyl, amino, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)O-alkyl and —C(O)OH; alkenyl; alkynyl; -alkyl-aryl; -alkyl-heteroaryl; -alkyl-heterocyclyl; -alkyl-carbocyclyl; -aryl-heteroaryl; -heteroaryl-aryl; -heteroaryl-heteroaryl; -aryl-aryl; -aryl (monocyclic or bicyclic); heteroaryl (monocyclic or bicyclic); heterocyclyl; or R2 together with R4 may form a carbocyclyl group optionally substituted by one or more alkyl groups; R3 represents alkyl, which may optionally be substituted by one or more groups selected from amino, halogen, hydroxylType: GrantFiled: November 8, 2007Date of Patent: June 22, 2010Assignee: Probiodrug AGInventors: Michael Thormann, Michael Altmstetter, Andreas Treml, Ulrich Heiser, Mirko Buchholz
-
Publication number: 20100152216Abstract: The present invention is directed to compounds of Formula I: (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: ApplicationFiled: March 7, 2008Publication date: June 17, 2010Inventors: Craig A. Stump, Ian M. Bell, Harold G. Selnick
-
Publication number: 20100144748Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.Type: ApplicationFiled: March 24, 2008Publication date: June 10, 2010Inventor: Satish K. Srivastava
-
Publication number: 20100130574Abstract: This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.Type: ApplicationFiled: September 30, 2009Publication date: May 27, 2010Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Kevin Eggan, Francesco Paolo DiGiorgio
-
Publication number: 20100130575Abstract: The present invention is related to a new series of chemical compounds, namely 3-benzyl-imidazolidine-2,4-dione substituted in the position 2 and/or 6 of benzyl ring by halogens as presented to the molecule named LPSF-PT-31, GIRSUPAN and its therapeutic use as drug with analgesic, sedative and adjuvant of anesthetics activities. The invention is also related to a process for production of said compounds as well as pharmaceutical compositions comprising them.Type: ApplicationFiled: May 5, 2008Publication date: May 27, 2010Inventors: Ivan Da Rocha Pitta, Maria Do Carmo Alves De Lima, Teresinha Goncalves Da Silva, Gisele Zapata Sudo, Suely Lins Galdino, Roberto Takashi Sudo
-
Patent number: 7723376Abstract: The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same.Type: GrantFiled: July 15, 2004Date of Patent: May 25, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Hwan Mook Kim, Gyoon Hee Han, Song Kyu Park, Chang Woo Lee, Sang Bae Han, Ki Hoon Lee, Yung Hee Kho, Jin Hyuk Yang, Bum Woo Park, Hyang Woo Lee, Jeung Whan Han, Dong Kyu Ryu, Jin Ha Lee, Tae Gyu Chun, Yong Kee Kim, Hee Yoon Lee, Bong Yong Lee, Jeom Yong Kim, Ji Duck Kim, Kyunga Yu, Sun Young Kim
-
Publication number: 20100125086Abstract: The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinising polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.Type: ApplicationFiled: September 4, 2009Publication date: May 20, 2010Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Stephan Schilling, Michael Wermann, Holger Cynis, Astrid Kehlen, Daniel Friedrich, Torsten Hoffmann, Kathrin Gans, Jens-Ulrich Rahfeld, Ulrich Heiser, Michael Almstetter, Robert Sommer, Ulf-Torsten Gaertner, Antje Hamann, Michael Thormann, Andreas Tremel
-
Publication number: 20100119620Abstract: A composition for anti-microbial effect in a water system such as a pulp and paper processing line with an aqueous slurry. The composition comprises a free chlorine-generating biocide comprising a chlorine source, urea, and an alkali in a concentration sufficient to provide a pH greater than 10, and typically at least pH 11.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Inventors: Laura E. Rice, Andrew J. Cooper, Robert L. Wetegrove, Michael V. Enzien
-
Patent number: 7713967Abstract: Compounds comprising a structure or a pharmaceutically acceptable salt thereof, or a prodrug thereof; wherein a dashed line represents the presence or absence of a bond are disclosed, wherein Y, A, B, and J are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 1, 2009Date of Patent: May 11, 2010Assignee: Allergan, Inc.Inventor: David W. Old
-
Patent number: 7709516Abstract: Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.Type: GrantFiled: June 14, 2006Date of Patent: May 4, 2010Assignee: Endorecherche, Inc.Inventors: Fernand Labrie, Rock Breton, Shankar Mohan Singh, René Maltais
-
Patent number: 7709515Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: November 16, 2004Date of Patent: May 4, 2010Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Publication number: 20100093817Abstract: This invention relates to new 6,8-difluorochroman-3-yl-1,3-dihydroimidazole-2-thiones, their preparation, and their use as a medicament.Type: ApplicationFiled: January 31, 2008Publication date: April 15, 2010Applicant: BIAL - PORTELA & CA S.A.Inventors: Patrício Manuel Vieira Araújo SOARES DA SILVA, David Alexander LEARMONTH, Alexander BELIAEV
-
Publication number: 20100092574Abstract: Disclosed is a method for controlling microbial growth in an aqueous system containing sulfite and/or bisulfite residues by addition of a peroxy compound at a pH of greater than 5. Also disclosed is a method for stabilizing an active halogen biocide in an aqueous system containing peroxide residues by addition of an N-hydrogen compound to the active halogen biocide before combining it with the peroxide containing aqueous system. Further disclosed is an optimized papermaking biocide program consisting of initially treating sulfite bleached pulp with peroxide followed by application of an N-hydrogen-stabilized active halogen compound to the paper producing white waters and an analytical method for determining peroxide concentrations in aqueous systems in the presence of sulfite and/or bisulfite.Type: ApplicationFiled: September 24, 2009Publication date: April 15, 2010Inventor: Philip Gerdon Sweeny
-
Patent number: 7683088Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.Type: GrantFiled: January 16, 2007Date of Patent: March 23, 2010Assignee: Schering CorporationInventors: Brian J. Lavey, Joseph A. Kozlowski, Guowei Zhou, Ling Tong, Wensheng Yu, Michael K. C. Wong, Bandarpalle B. Shankar, Neng-Yang Shih, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Aneta M. Micula, Seong-Heon Kim, De-Yi Yang, Razia Rizvi
-
Publication number: 20100063119Abstract: There is provided a novel LXR? agonist useful as a preventative and/or therapeutic agent for arteriosclerosis; arteriosclerosis such as those resulting from diabetes; hyperlipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: November 29, 2007Publication date: March 11, 2010Applicant: KOWA COMPANY, LTD.Inventors: Takayuki Matsuda, Ayumu Okuda, Minoru Koura, Yuki Yamaguchi, Sayaka Kurobuchi, Yuuichirou Watanabe, Kimiyuki Shibuya
-
Publication number: 20100063118Abstract: The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the hydantoin derivatives, including the treatment of HIV, AIDS and retrovirus-associated cancer.Type: ApplicationFiled: July 10, 2009Publication date: March 11, 2010Applicant: WyethInventors: Matthew W. Olson, Martin Di Grandi, Amarnauth Prashad
-
Patent number: 7674812Abstract: The present invention relates to a composition comprising two or more anti-irritants, each having at least about 7.2% oxygen content. In a separate embodiment, the composition may be defined to include a skin conditioning agent, a skin protectant agent, and an anti-irritant agent, each having an oxygen content of at least about 7.2%. The invention further comprises methods of treating and preventing skin conditions by applying the composition to the skin, and then optionally washing the skin.Type: GrantFiled: April 7, 2008Date of Patent: March 9, 2010Assignee: Medicis Pharmaceutical Corp.Inventors: Kuljit S. Bhatia, Bhiku G. Patel, Eugene H. Gans
-
Patent number: 7666892Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.Type: GrantFiled: May 5, 2008Date of Patent: February 23, 2010Assignee: AstraZeneca ABInventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
-
Patent number: 7662845Abstract: The invention provides compounds of formula in which L, X, Y, Z1, Z2, R1, R2, R3 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.Type: GrantFiled: August 7, 2006Date of Patent: February 16, 2010Assignee: AstraZeneca ABInventors: Krister Henriksson, Magnus Munck Af Rosenschöld
-
Publication number: 20100035950Abstract: Methods of controlling bacterial, yeast, and/or mold contamination of edible fruits or vegetables comprise applying thereto an aqueous microbiocidal composition stabilized against ultraviolet light-induced degradation formed from water and (A) at least one component selected from (I) a solid-state microbiocidal compound having at least one bromine atom per molecule; (II) an aqueous solution/slurry of a compound of (I); (III) a concentrated aqueous composition having an active bromine content of at least 50,000 ppm derived from water and (i) BrCl or BrCl and Br2 and (ii) overbased alkali metal sulfamate, where the relative proportions of (i) and (ii) give an atom ratio of nitrogen to active bromine greater than 0.93, and where the pH of the composition is greater than 7; (IV) a solid-state composition formed by dewatering a composition of (III), and (B) dissolved ascorbic acid or edible salt or ester thereof to inhibit ultraviolet light degradation of the solution.Type: ApplicationFiled: January 11, 2008Publication date: February 11, 2010Applicant: Albemarle CorporationInventors: Joe D. Sauer, George W. Cook, JR., William S. Pickrell
-
Patent number: 7655682Abstract: The present invention relates to a composition comprising two or more anti-irritants, each having at least about 7.2% oxygen content. In a separate embodiment, the composition may be defined to include a skin conditioning agent, a skin protectant agent, and an anti-irritant agent, each having an oxygen content of at least about 7.2%. The invention further comprises methods of treating and preventing skin conditions by applying the composition to the skin, and then optionally washing the skin.Type: GrantFiled: July 2, 2004Date of Patent: February 2, 2010Assignee: Medicis Pharmaceutical CorporationInventors: Kuljit S. Bhatia, Bhiku G. Patel, Eugene H. Gans
-
Patent number: 7652143Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.Type: GrantFiled: June 15, 2007Date of Patent: January 26, 2010Assignee: sanofi-aventis Deutschland GmbHInventors: Andreas Lindenschmidt, Holger Wagner, Jochen Beninga, Sven Grueneberg, Klaus-ulrich Weithmann